WebMar 1, 2024 · The SWORD study tests the hypothesis that a two-drug regimen of dolutegravir plus rilpivirine can maintain virologic suppression as well as the standard triple antiretroviral therapy. WebA team of researchers led by Professor Peijun Zhang, Director of the electron Bio-Imaging Centre (eBIC) at Diamond and Professor of Structural Biology at the University of …
The DIAMOND Study: Distensibility Improvement And …
WebNov 25, 2024 · The new research, published in Nature, found that low-cost nanodiamonds could be used to signal the presence of an HIV disease marker with a sensitivity many thousands of times greater than the... WebMar 3, 2014 · Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, … slushy fox
Surviving AIDS Appears To Require Permanent Triple-Drug Therapy
WebNov 9, 2024 · We included studies on HIV care cascade outcomes (testing, linkage to care, treatment initiation, treatment adherence, retention, and viral suppression), HIV health outcomes (new infections and mortality), non-HIV health outcomes, and … WebThis pilot study examined acceptability, feasibility, and initial adherence outcomes of providing adherence feedback using TFV-DP concentrations on patient- and provider-levels in Cape Town, South Africa. We enrolled 60 persons with HIV (PWH) receiving tenofovir-containing ART attending a primary health clinic. WebOct 21, 2014 · The purpose of this study is to demonstrate non-inferiority in efficacy while switching to a once-daily single-tablet regimen containing darunavir (DRV)/ cobicistat (COBI)/ emtricitabine (FTC)/ tenofovir alafenamide (TAF) (D/C/F/TAF tablet) relative to continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined … solar panels make your own